Cargando…
New developments in the management of Waldenström macroglobulinemia
Waldenström macroglobulinemia (WM) is a rare, immunoglobulin M -associated lymphoplasmacytic lymphoma. With the recent discoveries of CXCR warts, hypogammaglobulinemia, infections, and myelokathexis (WHIM) and MYD88 mutations, our understanding of the biology of WM has expanded substantially. While...
Autores principales: | Abeykoon, Jithma P, Yanamandra, Uday, Kapoor, Prashant |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5354523/ https://www.ncbi.nlm.nih.gov/pubmed/28331368 http://dx.doi.org/10.2147/CMAR.S94059 |
Ejemplares similares
-
Treatment paradigm in Waldenström macroglobulinemia: frontline therapy and beyond
por: Zanwar, Saurabh, et al.
Publicado: (2022) -
Waldenstrom macroglobulinemia: prognosis and management
por: Oza, A, et al.
Publicado: (2015) -
A prognostic index predicting survival in transformed Waldenström macroglobulinemia
por: Durot, Eric, et al.
Publicado: (2020) -
P1145: OUTCOMES AND TREATMENT PATTERNS AFTER FIRST RELAPSE IN PATIENTS WITH WALDENSTRÖM MACROGLOBULINEMIA
por: Tawfiq, R., et al.
Publicado: (2022) -
Increased glutathione utilization augments tumor cell proliferation in Waldenstrom Macroglobulinemia
por: Jalali, Shahrzad, et al.
Publicado: (2020)